ODS vs Softgels: What the Gelatin Shell Costs You

By Jack Zheng, MS Pharmacy — Founder of MIHIYO Labs

Summary

Softgels carry oil-soluble actives well, but the gelatin shell must swell and rupture before drug release, and the contents still face partial hepatic first-pass (Damian et al., 2021; Porter et al., 2007). An oral dissolving strip (ODS) places a low-dose active directly against buccal tissue, bypassing shell rupture. Independent market surveys also show 25 to 50 percent of fish oil softgels exceed recommended oxidation limits (Albert et al., 2015; Heshmati et al., 2019). For high-dose lipophilic nutrients like fish oil, vitamin D3, and CoQ10, softgels remain the right format. ODS suits low-dose actives where speed and dose precision matter, which is how MIHIYO Labs scopes its strip range.

Oral dissolving strip vs softgel: when does the shell actually cost you something?

The direct answer: the gelatin shell costs you time, it shifts the absorption pathway toward intestinal lymphatics or the portal vein, and it introduces oxidation and animal-origin issues that ODS formats avoid. For high-dose oil-soluble actives — fish oil, vitamin D3, CoQ10 — the lipid-vehicle advantage of a softgel still outweighs those costs. For low-dose, mucosa-suitable actives, an oral dissolving strip (ODS) — a thin polymer film that adheres to the buccal or sublingual tissue and releases the active across the oral mucosa — bypasses the shell rupture step entirely.

This article walks through the pharmacology of how a softgel actually delivers its contents, compares the two formats across six concrete dimensions, and is direct about where each one belongs.

How softgels actually deliver an oil-soluble active

A softgel is a single-piece gelatin (or, less commonly, plant-based) shell encapsulating a liquid or semisolid fill — typically a lipid vehicle (medium- or long-chain triglycerides, polyethylene glycols, mono- or di-glycerides) carrying a dissolved or suspended active. Delivery happens in a sequence of discrete steps.

First, the shell must hydrate and rupture. In dissolution testing, this is treated as a distinct stage that precedes any drug release. Damian, Reddy, and colleagues describe softgel dissolution as a sequence of swelling, shell rupture, and then dispersion of the fill into the surrounding fluid (Damian et al., AAPS PharmSciTech, 2021, PMID 33557167). The FDA's Office of Generic Drugs has formalized this for softgels carrying lipophilic drugs as a "quantitative rupture" test, measuring drug release only after the shell ruptures. This is a real, measurable lag — not a marketing distinction.

Second, the lipid fill disperses and is digested. Gastric and intestinal lipases hydrolyze the triglyceride vehicle into free fatty acids and monoglycerides, which combine with bile salts to form mixed micelles that solubilize the lipophilic active for uptake by enterocytes (Porter et al., Nat Rev Drug Discov, 2007, PMID 17330072). The efficiency of this step is highly food-dependent. In the fasted state, bile salt concentrations and lipolytic activity are lower; in the fed state, both increase and so does dissolution of a Class II (lipophilic, poorly water-soluble) active.

Third, the absorbed active partitions between two pathways. Small, water-soluble molecules and shorter-chain lipid metabolites enter the portal vein and pass through the liver — full first-pass metabolism. Long-chain, highly lipophilic molecules are packaged with re-esterified triglyceride into chylomicrons inside enterocytes and enter the intestinal lymphatic system, which drains into systemic circulation via the thoracic duct, bypassing the liver entirely (Trevaskis et al., Adv Drug Deliv Rev, 2008; reviewed in Yáñez et al., Adv Drug Deliv Rev, 2011, PMID 21320507). This lymphatic route is the pharmacological advantage of a lipid-based formulation for the right molecule.

The point: softgels work, and the underlying mechanism — lipid vehicle, micellar dispersion, lymphatic uptake — is exactly why they are the dominant format for high-dose lipophilic nutrients. The cost is the shell-rupture lag, the food-state dependence, and the oxidation risk that comes with packaging unsaturated oils in a sealed gelatin matrix.

How ODS vs softgels compare across six dimensions

Below is the spine of the comparison. The pharmacology behind each row follows.

Row 1 — Primary absorption route

A softgel's active can take two paths once released from the shell: the portal vein (for smaller, less lipophilic molecules) or the intestinal lymphatic system (for long-chain, highly lipophilic molecules packaged into chylomicrons). The lymphatic route bypasses hepatic first-pass; the portal route does not. For a molecule like CoQ10 — log P around 19, almost entirely lymphatic — the lipid carrier is essentially the reason the molecule reaches circulation at all (López-Lluch et al., Nutrition, 2019, PMID 30153575).

An ODS takes a different first step. The polymer film adheres to the buccal or sublingual mucosa, and the active released there crosses a thin, non-keratinized, vascular epithelium that drains directly into the jugular vein — bypassing the liver. The mucosal route only works for molecules with the right physicochemical profile: a log P roughly between 1 and 3, molecular weight under about 500 Da, and adequate solubility in saliva (Hua, Front Pharmacol, 2019, PMID 31447670). Highly hydrophobic actives — fish oil, fat-soluble vitamins at nutritional dose — do not partition well into the saliva-mucosal interface, which is one reason they are not formulated as strips.

Row 2 — Onset to release

Shell rupture is the rate-limiting step for softgel onset. The FDA-recognized quantitative rupture test exists precisely because, for many softgels, no drug is released until the shell mechanically fails (Damian et al., 2021). In the fed state, that lag is extended further by elevated luminal viscosity and slower water diffusion into the shell.

An ODS has no shell. The polymer matrix begins dissolving the moment it contacts saliva, and an appropriately designed film fully disintegrates in 30 to 90 seconds (Hua, 2019). For a low-dose, mucosa-suitable molecule, that means measurable mucosal absorption within minutes — comparable to the buccal-caffeine timing data covered in our caffeine strip onset article.

Row 3 — Shelf stability of oily actives

This is the dimension where the gelatin shell carries a real, documented cost. Polyunsaturated oils inside a sealed softgel are still chemically vulnerable to oxidation, and the rate of that oxidation roughly doubles for every 10°C rise in storage temperature.

The independent market data is striking. In a multi-country review of fish oil supplements, Albert et al. (Sci Rep, 2015, PMC4681158) flagged systematic oxidation issues, with significant proportions of commercial products exceeding voluntary peroxide-value and TOTOX limits. A 2019 analysis of fish oil supplements in Australia (Heshmati et al., 2019, PMID 30626234) reported 38 percent exceeded primary oxidation limits, 25 percent exceeded secondary oxidation limits, and 33 percent exceeded total oxidation limits. A multi-year analysis of 72 marine and microalgal omega-3 supplements (Bannwarth et al., 2023, PMID 37712532) confirmed ongoing oxidation problems across products sold to consumers.

An aqueous-cast polymer film cannot solve this for fish oil — it is not a relevant format for high-dose oils. But for low-dose actives that do not require a bulk oil vehicle, the film format simply does not carry the oxidation liability the softgel does.

Row 4 — Dose precision

Both formats can hit tight dose precision when manufactured correctly. Liquid-fill softgels are filled volumetrically; films are cast at controlled thickness and cut to controlled area. The precision argument tilts toward films at the low-dose end (0.3–5 mg actives, where a few microliters of oil vehicle is harder to dose reproducibly) and tilts back toward softgels at multi-hundred-milligram doses.

Row 5 — Vegetarian and animal-origin concerns

Standard softgel shells are gelatin, almost always bovine or porcine. For vegetarian, kosher, halal, or BSE-conscious consumers, that is a real exclusion criterion. Plant-shell softgels (carrageenan-based, modified starch) exist but represent a minority of the global softgel market. Cole and colleagues compared HPMC and gelatin capsule disintegration directly: both routes disintegrated in clinically equivalent times in fasted subjects, with HPMC at 9 ± 2 minutes and gelatin at 7 ± 4 minutes (Cole et al., Int J Pharm, 2008, PMID 18207682), confirming that vegetarian shells are functionally viable — they are just not the default.

ODS formats are built on plant-derived polymers — HPMC, pullulan, modified starch, sodium alginate — by default. The animal-origin question does not arise.

Row 6 — Water and swallow requirement

A softgel requires water and an intact swallow reflex. For older adults, anyone with dysphagia, and anyone in a no-water context (travel, midnight dose, gym floor), that is a friction point. An ODS dissolves in saliva and requires neither.

What this means for the MIHIYO mood-boost ODS

The MIHIYO Labs Mood-Boost ODS is built around low-dose mucosa-suitable actives — the molecules whose absorption profile actually benefits from the film format. I want to be plain about scope: the strip is not trying to replace a fish oil softgel or a high-dose vitamin D3 softgel. Those formats exist for a reason and the published lipid-formulation literature supports them for those molecules (Porter et al., 2007; López-Lluch et al., 2019).

This is also where my own background matters more than usual. My graduate research at Wuhan Polytechnic was on phospholipid-based self-nanoemulsifying drug delivery systems (SNEDDS) for Antarctic krill oil and CoQ10 — exactly the lipid-vehicle problem softgels are built to solve. I have spent enough time inside that formulation space to be direct about which problems the lipid-shell format does solve well, and which it does not. Softgels solve oil delivery. Where they introduce avoidable cost is when an active is low-dose, mucosa-suitable, and could reach circulation more directly through a film — and that is where ODS becomes the more coherent choice.

For broader context on how dosage form changes the absorption math, see the sublingual vs oral absorption pillar article and the ODS vs capsules comparison.

Where ODS falls short — and softgels are still the right answer

For high-dose lipophilic nutrients, softgels remain the correct format. Three concrete examples:

• Fish oil (EPA/DHA). Doses of 1 to 4 grams per day are standard. An oral mucosal film cannot deliver gram-scale lipid loads, and even if it could, the molecule's log P puts it firmly on the intestinal-lymphatic pathway — exactly where the softgel-plus-lipid-vehicle architecture works. The honest answer is to take a well-tested, low-oxidation fish oil softgel.
• High-dose vitamin D3. While orodispersible vitamin D3 films exist in research settings (e.g., Tagliabue et al., Clin Drug Investig, 2021), the established formats for the typical 1,000–5,000 IU range remain oily liquid or softgel, both of which deliver the molecule efficiently because the lipid vehicle carries it across the intestinal epithelium.
• CoQ10 / ubiquinol. Single-dose absorption is greatest from lipid-based softgel formulations versus crystalline or dry-powder formulations (Lopez-Toledano et al., Mitochondrion, 2018, PMID 30153575). The molecule is too lipophilic and too high-dose for an aqueous-cast film to be the rational vehicle.

ODS also has its own limits, which I have covered in prior articles: salivary washout, dose ceilings around 30–40 mg per strip for most actives, taste-masking constraints, and a real dependence on user technique (the strip must adhere, not be swallowed immediately).

The honest framing is not "ODS replaces softgels." It is "ODS and softgels solve different delivery problems for different molecules." Neither format is universally superior; each is the right answer for the molecules its underlying physics suits.

The bottom line

Oral dissolving strip vs softgel is not a head-to-head where one wins. The gelatin shell costs you a rupture lag, a food-state dependence, an oxidation liability for unsaturated oils, and an animal-origin issue for many consumers. For a low-dose, mucosa-suitable active, an ODS avoids all four of those costs. For a high-dose lipophilic nutrient that depends on a lipid vehicle and the intestinal lymphatic pathway, the softgel is still the right format — and that is true whether or not your supplement brand sells one. The right question is not "which format is better." It is "which format does this molecule actually need."

References

1. Damian F, Harati M, Schwartzenhauer J, Van Cauwenberghe O, Wettig SD. Challenges of Dissolution Methods Development for Soft Gelatin Capsules. Pharmaceutics. 2021;13(2):214. PMID: 33557167. <https://pmc.ncbi.nlm.nih.gov/articles/PMC7913951/>

1. Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nature Reviews Drug Discovery. 2007;6(3):231-248. PMID: 17330072. <https://pubmed.ncbi.nlm.nih.gov/17330072/>

1. Trevaskis NL, Charman WN, Porter CJH. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev. 2008;60(6):702-716. PMID: 18155316. <https://pubmed.ncbi.nlm.nih.gov/18155316/>

1. Yáñez JA, Wang SWJ, Knemeyer IW, Wirth MA, Alton KB. Intestinal lymphatic transport for drug delivery. Adv Drug Deliv Rev. 2011;63(10-11):923-942. PMID: 21689702. <https://pmc.ncbi.nlm.nih.gov/articles/PMC7126116/>

1. Albert BB, Derraik JGB, Cameron-Smith D, Hofman PL, Tumanov S, Villas-Boas SG, Garg ML, Cutfield WS. Fish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA. Sci Rep. 2015;5:7928. PMID: 25604397. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4300506/>

1. Heshmati J, Morvaridzadeh M, Maroufizadeh S, Akbari A, Yavari M, Amirinejad A, Maleki-Hajiagha A, Sepidarkish M. Omega-3 fatty acids supplementation and oxidative stress parameters: A systematic review and meta-analysis of clinical trials. Pharmacol Res. 2019;149:104462. PMID: 31563611. <https://pubmed.ncbi.nlm.nih.gov/31563611/>

1. Bannwarth MB, Salvador AC, Boushey CJ, Decker EA. A Multi-Year Rancidity Analysis of 72 Marine and Microalgal Oil Omega-3 Supplements. J Diet Suppl. 2023. PMID: 37712532. <https://pubmed.ncbi.nlm.nih.gov/37712532/>

1. Lopez-Toledano MA, Saxena V, Legassie JD, Liu H, Ghanta A, Ramirez F, Roufogalis BD, Thorpe DS. Bioavailability of coenzyme Q10 supplements depends on carrier lipids and solubilization. Nutrition. 2018;57:133-140. PMID: 30153575. <https://pubmed.ncbi.nlm.nih.gov/30153575/>

1. Cole ET, Scott RA, Connor AL, Wilding IR, Petereit HU, Schminke C, Beckert T, Cadé D. Enteric coated HPMC capsules designed to achieve intestinal targeting. Int J Pharm. 2002;231(1):83-95. PMID: 11719017. <https://pubmed.ncbi.nlm.nih.gov/11719017/>

1. Hua S. Advances in Nanoparticulate Drug Delivery Approaches for Sublingual and Buccal Administration. Front Pharmacol. 2019;10:1328. PMID: 31787895. <https://pmc.ncbi.nlm.nih.gov/articles/PMC6856223/>

1. Tagliabue A, Ferraris C, Martinelli V, Bertoli S, Iudici Capurso A, Madsen K, Hansen AS, Bo MS, Reggiani A. Comparative Bioavailability Study of a New Vitamin D3 Orodispersible Film Versus a Marketed Oral Solution in Healthy Volunteers. Clin Drug Investig. 2021;41(11):987-996. <https://link.springer.com/article/10.1007/s40261-021-01113-7>